Get notified when QTTB files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Offering Price of $18.25 Per Share Is Significantly Higher Than the Last Reported Sale Price of $11.21 On July 10, 2026 (new) — The 63% premium to the last close may indicate aggressive pricing that could lead to poor aftermarket performance.
- Immediate Dilution of $8.13 Per Share (new) — New investors pay $18.25 for shares with a net tangible book value of only $10.12, a 44.5% dilution relative to the offer price.
- No Public Trading Market For the Pre-funded Warrants (new) — Warrant holders may be unable to sell their warrants, reducing their value and liquidity.
Q32 Bio prices $200M offering at $18.25/share, a 63% premium to last close, with $187.6M net proceeds for bempikibart development
Filed July 15, 2026 · ~2 min read
Key Changes
-
high
Q32 Bio is selling 6,027,399 common shares at $18.25 each, plus pre-funded warrants for up to 4,931,506 shares at $18.2499, for total gross proceeds of about $200M.
The Offering verify on EDGAR → -
high
The company estimates net proceeds of $187.6M ($215.8M if underwriters' option fully exercised) after underwriting discounts and expenses.
Use of Proceeds verify on EDGAR → -
high
Proceeds are intended for working capital, research, clinical development, and commercialization, specifically to advance bempikibart into future clinical trials.
Use of Proceeds verify on EDGAR →
4 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (MU 10-K) is open in full — no account needed.
Partner
Trade QTTB commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 1, 2026 · How we verify